Signaturefd LLC Grows Stake in Moderna, Inc. (NASDAQ:MRNA)

Signaturefd LLC boosted its position in Moderna, Inc. (NASDAQ:MRNA) by 17.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,618 shares of the company’s stock after purchasing an additional 535 shares during the period. Signaturefd LLC’s holdings in Moderna were worth $150,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Allworth Financial LP increased its stake in Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after purchasing an additional 281 shares in the last quarter. Howard Capital Management Inc. increased its position in Moderna by 3.1% during the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after buying an additional 297 shares in the last quarter. Larson Financial Group LLC increased its position in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after buying an additional 317 shares in the last quarter. Empowered Funds LLC increased its position in Moderna by 6.6% during the third quarter. Empowered Funds LLC now owns 5,199 shares of the company’s stock worth $347,000 after buying an additional 322 shares in the last quarter. Finally, Commonwealth Equity Services LLC increased its position in Moderna by 0.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company’s stock worth $3,099,000 after buying an additional 345 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

NASDAQ:MRNA opened at $32.66 on Friday. The business’s 50-day moving average is $34.91 and its two-hundred day moving average is $45.86. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The firm has a market capitalization of $12.60 billion, a PE ratio of -3.52 and a beta of 1.86.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Citigroup assumed coverage on Moderna in a research report on Thursday, March 13th. They set a “neutral” rating and a $40.00 price target for the company. Leerink Partners dropped their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, January 16th. Bank of America dropped their price target on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.